Medicenna
Vancouver
British Columbia
Canada
110 articles with Medicenna
-
Medicenna to Present at the Oppenheimer 33rd Annual Healthcare Conference
3/2/2023
Medicenna Therapeutics Corp. today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will participate in a fireside chat at the Oppenheimer 33rd Annual Healthcare Conference, which is scheduled to take place virtually from March 13 – 15, 2023.
-
Medicenna Reports Third Quarter Fiscal 2023 Financial Results and Operational Highlights
2/7/2023
Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced its financial results and operational highlights for the quarter ended December 31, 2022, and that the Phase 1/2 ABILITY study of MDNA11 has advanced to a sixth dose escalation cohort.
-
Medicenna to Present at the 2023 Guggenheim Oncology Conference
1/31/2023
Medicenna Therapeutics Corp. today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will participate in a fireside chat at the 2023 Guggenheim Oncology Conference, which is scheduled to take place from February 8 – 9, 2023.
-
Medicenna to Announce Third Quarter Fiscal 2023 Financial Results and Operational Highlights on Tuesday, February 7, 2023
1/26/2023
Medicenna Therapeutics Corp. today announced that it will host a conference call and live webcast on February 7, 2023 at 8:30 AM ET to report its third quarter fiscal 2023 financial results and operational highlights.
-
Medicenna Presents Updated Clinical Data from Dose Escalation Portion of Phase 1/2 ABILITY Study of MDNA11 at the SITC Annual Meeting
11/10/2022
Medicenna Therapeutics Corp. today announced new safety, pharmacokinetic (PK), and pharmacodynamic (PD) data from the first four dose escalation cohorts of the Phase 1/2 ABILITY study of MDNA11, the Company’s “beta-only” long-acting IL-2 super-agonist.
-
Medicenna Reports Second Quarter Fiscal 2023 Financial Results and Operational Highlights
11/4/2022
Medicenna today announced its financial results and operational highlights for the quarter ended September 30, 2022. All dollar amounts are in Canadian currency unless otherwise noted.
-
Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
10/28/2022
Medicenna Therapeutics Corp. announced that on October 25, 2022, it received a notice from the Nasdaq Stock Market LLC, stating that the Company is not in compliance with the minimum bid price requirement of US$1.00 per share under the Nasdaq Listing Rule 5450 based upon the closing bid price of the Company’s common stock for the 30 consecutive business days prior to the date of the Notice.
-
Medicenna Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting
10/5/2022
Medicenna Therapeutics Corp. announced the acceptance of two abstracts for poster presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting, which is taking place both virtually and in-person at the Boston Convention and Exhibition Center in Boston, MA, from November 8 – 12, 2022.
-
Medicenna Reports Confirmed Partial Response in Pancreatic Cancer and Clinical Update on MDNA11’s Monotherapy Dose Escalation Portion of the Ongoing Phase 1/2 ABILITY Study
9/28/2022
Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced new clinical data on anti-tumor activity from the Phase 1/2 ABILITY study of MDNA11, the Company’s “beta-only” long-acting IL-2 super-agonist.
-
Medicenna Presents Preclinical Data Demonstrating Anti-Tumor Activity of its Anti-PD1-IL-2 BiSKIT and Long-Acting IL-4/IL-13 Super-antagonist at Cytokines 2022
9/22/2022
Medicenna Therapeutics Corp. today announced presentation of data from two preclinical programs that demonstrate the anti-tumor activity of the Company’s anti-PD1-IL-2 (aka MDNA223) BiSKIT (Bi-functional SuperKines for ImmunoTherapy) and long-acting IL-4/IL-13 super-antagonist (aka MDNA413).
-
Medicenna Announces Results of Annual Meeting of Shareholders
9/21/2022
Medicenna Therapeutics Corp., a clinical stage immuno-oncology company, announced the voting results from the Company’s annual meeting of shareholders held today, September 21, 2022.
-
Medicenna Announces Clinical Collaboration with Merck to evaluate MDNA11 in combination with KEYTRUDA® (pembrolizumab) in ABILITY Trial
9/13/2022
Medicenna Therapeutics Corp. today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside the United States and Canada) to evaluate MDNA11, Medicenna’s “beta-only” long-acting IL-2 super-agonist in combination with KEYTRUDA ® (pembrolizumab).
-
Medicenna Announces Closing of Public Offering of Units Raising US$20 Million to Advance Pipeline
8/11/2022
Medicenna Therapeutics Corp. is pleased to announce the closing of its previously announced marketed underwritten public offering of units of the Company in Canada and in the United States at a price to the public of US$1.50 per Unit, for aggregate gross proceeds to the Company of approximately US$20 million, before deducting underwriting commissions and Offering expenses and excluding any proceeds the Company may receive from the exercise of the underlying warrants.
-
Medicenna Announces Pricing of US$20 Million Public Offering of Units
8/9/2022
Medicenna Therapeutics Corp. announced today that it has priced its previously-announced marketed underwritten public offering of 13,333,334 units (the “Unit”) of the Company in the Canada and in the United States at a price to the public of US$1.50 per Unit (the “Offering”).
-
Medicenna Announces the Launch of a Marketed Underwritten Public Offering of Units - Aug 08, 2022
8/8/2022
Medicenna Therapeutics Corp., a clinical stage immunotherapy company, announced the launch of a marketed underwritten public offering of units of the Company in the United States.
-
Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11’s Single Agent Anti-Cancer Activity in the Phase 1/2 ABILITY Study
7/27/2022
Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company, today announced new clinical data on safety, pharmacodynamics and anti-tumor activity from the Phase 1/2 ABILITY study of MDNA11, the Company’s long-acting IL-2 super agonist.
-
Medicenna Reports Fiscal Year 2022 Financial Results and Operational Highlights
6/22/2022
Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced its financial results and operational highlights for the fiscal year ended March 31, 2022.
-
Medicenna Strengthens Intellectual Property Protection for Superkine Platform with Issuance of U.S. Patent
6/9/2022
Patent covers composition and methods of treating degenerative diseases via administration of IL-4 and IL-13 Empowered Superkines.
-
Medicenna to Announce Fiscal Year 2022 Financial Results and Operational Highlights on Wednesday, June 22, 2022
6/7/2022
Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on June 22, 2022 at 8:30 AM ET to report its fiscal year 2022 financial results and operational highlights.
-
Achilles dosed the first patient in a Phase I/IIa advanced NSCLC trial, Logic Bio's pediatric methylmalonic acidemia study is back up and running and another look at Roche's TIGIT flop.